CEO Executive AssistantRegulatory affairs is a specialized domain where pharmaceutical CEOs must balance two competing risks. Under-delegation leaves the CEO micromanaging technical regulatory activities they are not best positioned to lead. Over-delegation means missing strategic regulatory decisions that can define a company’s trajectory.
This guide provides a clear delegation framework for pharma CEOs navigating regulatory affairs responsibilities.
The CEO’s Strategic Regulatory Role
The pharma CEO’s regulatory involvement is legitimate and important, but should be concentrated at the strategic level:
Regulatory agency senior relationships. At key developmental moments, CEO-to-commissioner or CEO-to-director-level engagement with the FDA or EMA can be appropriate, particularly for breakthrough designations, major disputes, or sensitive program discussions.
Regulatory strategy approval. Major regulatory strategy decisions such as the target indication, the primary endpoint, the clinical development path, and the regulatory designation pursued require CEO understanding and approval because they have significant commercial and financial implications.
Investor disclosure related to regulatory events. Regulatory events often trigger disclosure obligations. The CEO, working with legal counsel and investor relations, manages the disclosure strategy.
Regulatory crisis response. A clinical hold, a Complete Response Letter, or a public safety communication related to an approved product requires CEO-level response coordination.
Regulatory investment decisions. Decisions about regulatory submission timelines, resource allocation for submissions, and investments in regulatory capabilities are CEO-approved budget decisions.
What to Delegate
To the Chief Regulatory Officer or VP of Regulatory Affairs
The regulatory leadership team owns the full operational regulatory function:
Regulatory submission strategy and execution. IND submissions, NDA and BLA preparation, MAA preparation, and all other regulatory submissions are regulatory affairs responsibilities. The CEO is briefed on strategy and key decisions but does not manage submissions.
FDA and EMA meeting preparation and conduct. Pre-IND meetings, end-of-Phase 2 meetings, pre-NDA meetings, and advisory committee preparation are owned by the regulatory affairs team. The CEO may attend specific meetings where senior executive presence is strategically valuable.
Regulatory designation strategy. Pursuing Breakthrough Therapy, Fast Track, Orphan Drug, or Priority Review designations is a regulatory affairs strategy function, implemented in partnership with clinical and commercial teams.
CMC regulatory strategy. Chemistry, Manufacturing, and Controls regulatory requirements are managed by regulatory affairs in coordination with manufacturing and quality.
Post-approval regulatory maintenance. Annual reports, labeling updates, post-marketing commitment management, and lifecycle regulatory activities are regulatory operations functions.
International regulatory submissions. Submissions to international regulatory authorities in ex-US markets are regulatory affairs responsibilities.
Regulatory intelligence monitoring. Tracking regulatory guidance documents, policy changes, and industry precedents is a regulatory affairs research function.
To the Medical Affairs Team
Medical Information compliance. The regulatory boundary between medical information and promotional activities is a medical affairs and regulatory affairs joint responsibility.
Labeling discussions with regulatory. The medical affairs team participates in labeling negotiations in coordination with regulatory affairs.
To the Legal and Compliance Team
Regulatory compliance program. Ensuring sales and marketing activities comply with FDA promotional regulations is a legal and compliance function supported by regulatory affairs.
Governance Structures for Regulatory Delegation
Regulatory Strategy Committee
A regulatory strategy committee, typically including the CMO, CRO, VP of Regulatory Affairs, and VP of Clinical Operations, reviews and approves major regulatory strategy decisions. The CEO may chair or participate in key milestone reviews but delegates routine committee management.
Regulatory Milestone Calendar
A regulatory calendar tracking all upcoming submission deadlines, regulatory meetings, and agency response dates should be maintained by the regulatory affairs team and provided to the CEO in a monthly executive summary.
Regulatory Risk Dashboard
A quarterly regulatory risk assessment covering programs with material regulatory uncertainty helps the CEO stay informed without operational involvement. The regulatory team prepares this; the CEO uses it for board reporting and investor communications.
Common Pharma CEO Regulatory Delegation Mistakes
Bypassing the regulatory team in agency conversations. CEOs who develop direct relationships with FDA staff outside the regulatory affairs framework create confusion, undermine the regulatory team’s credibility, and risk miscommunication. Channel senior FDA interactions through the regulatory affairs function.
Approving regulatory strategy without scientific input. When the CEO overrules regulatory and clinical recommendations based on business pressure (approving an accelerated regulatory path the technical team does not support), the results are often poor. Delegate strategy development; approve strategy with technical grounding.
Under-staffing regulatory for late-stage programs. Capital-intensive late-stage trials require significant regulatory affairs investment. CEOs who under-resource regulatory for NDA or BLA preparation create avoidable submission risks.
Pharma CEOs building comprehensive C-suite delegation models will find relevant frameworks in what pharmaceutical biotech CEOs delegate to their chief of staff.
For broader pharmaceutical executive delegation practices, how to delegate tasks to executive assistant in pharmaceutical and biotech covers support staff applications.
Conclusion
Regulatory affairs is one of the most technically specialized functions in pharmaceutical organizations. The pharma CEO who builds strong regulatory leadership, establishes clear governance structures, and maintains strategic oversight through regular reporting will navigate regulatory challenges more effectively than the CEO who tries to personally direct regulatory operations.
Invest in regulatory talent. Trust the regulatory strategy. Engage at strategic moments. The regulatory pathway will be clearer, and the CEO will lead more effectively.
For pharmaceutical regulatory strategy insights, see McKinsey.com/industries/life-sciences.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.